Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.
Saved in:
| Title: | Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer. |
|---|---|
| Authors: | Gaudian K; Washington University School of Medicine in St. Louis, St. Louis, MO, United States., Koh MJ; School of Medicine, Georgetown University, Washington, DC, United States., Koh MJ; School of Medicine, Georgetown University, Washington, DC, United States., Collins RR; College of William and Mary, Williamsburg, VA, United States., Eden S; Systems Medicine Program, Georgetown University Medical Center, Washington, DC, United States., Zwart Z; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Danner M; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States., Zwart A; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Fallick M; Novartis, US Medical Affairs, Oncology, East Hanover, NJ, United States., Kumar D; Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States., Leger P; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Dawson NA; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Suy S; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States., Collins SP; Department of Radiation Oncology, University of South Florida (USF) Health Morsani College of Medicine, Tampa, FL, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Jan 30; Vol. 15, pp. 1540482. Date of Electronic Publication: 2025 Jan 30 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1540482 |
